EQT and Goldman Sachs completes Parexel acquisition

EQT Private Equity and Goldman Sachs have closed its previously announced buyout of Parexel, a global clinical research organization, for $8.5 billion.

To view this content, you need to sign in.


You should only be asked to sign in once. Not the case? Click here


Register now to access this content and more for free.

Share this